Nearer to engineering new kidney tissue With an internationally shortage of kidneys for patients who need kidney transplants, researchers are diligently attempting to find methods to engineer new kidney tissue from a patient's have cells or another resource. They've come a step closer to realizing that goal with a breakthrough described in an upcoming Journal of the American Culture of Nephrology research several month . The advance could lead to more options for folks with kidney failure, in addition to better tools for understanding kidney illnesses and how to treat them.

Clivatuzumab tetraxetan shows promising results in individuals with metastatic pancreatic cancer Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to take care of cancer and other critical diseases, announced that its proprietary antibody today, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine continues to create promising efficacy outcomes in sufferers with previously untreated, inoperable, locally advanced or metastatic pancreatic cancer. At the 2010 American Society of Clinical Oncology annual conference, Dr.